Discuss stages of fracture h3aling 5 marks bone substitutes 5 marks ms ortho ntruhs theory exam structure answer
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have sufficient, high-quality information from the latest orthopaedic textbooks (Campbell's 15th Ed 2026, Rockwood & Green's 10th Ed 2025, Bailey & Love's 28th Ed) to write comprehensive exam answers. Let me compose the full structured response.
MS Ortho NTRUHS Theory Exam - Structured Answers
STAGES OF FRACTURE HEALING (5 Marks)
Introduction
Fracture healing is a complex biological process that requires recruitment of appropriate cells (fibroblasts, macrophages, chondroblasts, osteoblasts, osteoclasts) and expression of the appropriate genes at the right time and anatomic location. It restores injured bone to its original state through three major biological phases - inflammatory, endochondral bone formation, and coupled remodeling.
Types of Fracture Healing
There are two modes of fracture healing:
-
Direct (Primary) Bone Healing - occurs when bone ends are in absolute compression with cortical apposition and no movement. Osteoclastic cutting cones cut across the fracture line, with osteoblasts following and laying down lamellar bone directly across the fracture - no callus is formed.
-
Indirect (Secondary) Bone Healing - the most common form. Involves formation of callus, governed by Perren's Strain Theory:
- Strain >100%: fibrous tissue forms
- Strain <10%: soft callus forms
- Strain <2%: hard callus and progressive mineralization
Four Stages of Indirect Fracture Healing
(Einhorn's Classification - Campbell's Operative Orthopaedics 15th Ed, 2026)
Stage 1 - Hematoma Formation (Days 1-5)
- Rupture of blood vessels at the fracture site causes hematoma formation
- Hematopoietic cells and clots within the hematoma form the beginning framework of healing
- Inflammatory cells invade and initiate lysosomal degradation of necrotic tissue
- Key mediators: prostaglandins, interleukins, growth factors (TGF-β, PDGF, FGF)
Stage 2 - Granulation Tissue / Soft Callus Formation (Days 4-14)
- The reparative phase begins around day 4-5 with invasion of pluripotential mesenchymal cells
- These differentiate into fibroblasts, chondroblasts, and osteoblasts
- A soft cartilaginous callus is formed
- Resultant angiogenesis within periosteal tissues and marrow space routes appropriate cells to the fracture site
- Granulation tissue bed is established
- Radiologically: no change visible yet
Stage 3 - Bony (Hard) Callus Formation (Weeks 2-12)
- The cartilaginous callus undergoes endochondral ossification and is replaced with woven bone
- At the end of this process, calcified callus of immature (woven) bone remains
- Radiologically: visible callus around the fracture ends; fracture line begins to blur
Stage 4 - Remodeling (Months to Years)
- Begins when mineralization stiffens and strengthens the newly formed bone
- Woven bone is replaced by lamellar bone
- The medullary canal is restored
- Bone returns to normal or near-normal morphology and mechanical strength following Wolff's Law
- Radioisotope studies show increased activity long after clinical and radiographic union
Four Types of New Bone Formation During Healing
- Osteochondral ossification
- Intramembranous ossification
- Appositional new bone formation
- Osteonal migration (creeping substitution)
Factors Affecting Fracture Healing
| Systemic Factors | Local Factors | Treatment Factors |
|---|---|---|
| Age, nutritional status | Severity of injury | Extent of surgical trauma |
| Hormonal status, vitamins | Neurovascular disruption | Type of fixation (rigid vs. flexible) |
| Diabetes, malignancy | Bone loss, soft-tissue interposition | Fracture displacement |
| Smoking (most notable inhibitor) | Infection | Overdistraction |
| NSAIDs (conflicting evidence) | High-energy trauma | Load-induced deformation |
Clinical union = fracture site stable and pain-free. Radiographic union = trabeculae/cortex crossing the fracture line on plain X-ray.
BONE SUBSTITUTES (5 Marks)
Introduction
Although autogenous iliac crest bone remains the gold standard for filling bone defects, its use increases morbidity (donor site pain, cosmetic defect, fatigue fracture, heterotopic ossification) and the available volume is limited. This has driven development of bone graft substitutes.
Three Mechanisms of Bone Graft Function
(Rockwood & Green's 10th Ed, 2025; Campbell's 15th Ed, 2026)
| Mechanism | Definition |
|---|---|
| Osteogenesis | Ability of viable cellular elements within a graft to directly synthesize new bone (requires pluripotent cells, scaffold, and growth factors) |
| Osteoinduction | Ability to recruit and differentiate host mesenchymal stem cells into chondroblasts and osteoblasts (mediated by BMPs, FGF, PDGF, VEGF) |
| Osteoconduction | Ability to act as a passive scaffold, facilitating blood vessel ingrowth and bone formation into the graft structure |
Classification of Bone Graft Substitutes
(Laurencin Classification - Campbell's Operative Orthopaedics 15th Ed, 2026)
1. Allograft-Based Substitutes
- Available as: fresh-frozen, freeze-dried, irradiated (electron beam/gamma ray), decalcified
- Demineralized Bone Matrix (DBM): Decalcified allograft containing osteoinductive proteins (BMPs). Available as putty, gel, paste, powder, strips. Minimally processed; FDA approval not required.
- Variability in osteoinductive strength exists between products depending on donor, processing, and carrier
- Disease transmission is a rare but documented risk
2. Factor-Based Substitutes
- Include natural and recombinant growth factors
- Recombinant human BMP-2 (rhBMP-2): Used in spine fusion and long bone nonunions
- Risk: associated with increased cancer events, soft-tissue inflammation (16% complication rate in some studies), and retrograde ejaculation with anterior lumbar fusion
- rhBMP-7 (OP-1), TGF-β, FGF, PDGF, VEGF, PTH, Statins are other factors investigated
3. Cell-Based Substitutes
- Use cells to produce new bone
- Bone marrow aspirate (BMA): Contains mesenchymal stem cells with osteogenic potential; when combined with osteoconductive scaffold provides osteogenic mechanism
- Mesenchymal stem cell therapy (autograft or allograft): Considered investigational by FDA
4. Ceramic-Based Substitutes
- Use ceramics as scaffold for bone growth (osteoconductive only - lack osteogenic/osteoinductive properties)
| Type | Resorption Rate | Key Feature |
|---|---|---|
| Hydroxyapatite (HA) | Very slow (>10 years on X-ray) | High structural stability, good long-term scaffold |
| Tricalcium phosphate (TCP) | 6-18 months | Faster resorption; promotes bone replacement |
| Calcium phosphate cement | 6 months-10 years | Highest compressive strength of ceramics |
| Calcium sulfate | 6-12 weeks | Fastest resorption; allows rapid replacement by native bone; used since 1892 |
| Bioactive glass | Variable | Bonds directly to bone; osteoconductive |
5. Polymer-Based Substitutes
- Use biodegradable polymers (alone or with other materials) as scaffold
- Can be tailored for degradation rate and mechanical properties
6. Miscellaneous
- Coral and sponge skeleton (marine sources) - natural calcium carbonate scaffold
- Composites combining multiple mechanisms (e.g., allograft + bone marrow aspirate = osteoconductive + osteogenic)
Summary Table - Classification (Campbell's eTable 2.1)
| Property | Description | Examples |
|---|---|---|
| Osteoconduction | Passive porous scaffold | Calcium sulfate, ceramics, calcium phosphate cements, collagen, bioactive glass, synthetic polymers |
| Osteoinduction | Induces stem cell differentiation | DBM, BMPs, growth factors, gene therapy |
| Osteogenesis | Directly lays down new bone | Bone marrow aspirate |
| Combined | More than one property | Composites |
Complications of Bone Graft Substitutes
- rhBMP-2: increased cancer risk, soft tissue inflammation, retrograde ejaculation
- TCP + calcium sulfate: 16% soft-tissue inflammation rate
- Use in skeletally immature patients not FDA-approved (risk of injury from extra bone growth stimulus)
- DBM: variable efficacy, risk of infection
Sources:
- Campbell's Operative Orthopaedics 15th Ed 2026, Chapter 58 (Fracture Healing, Bone Graft Substitutes)
- Rockwood and Green's Fractures in Adults 10th Ed 2025, Chapter 3 (Bone Graft and Bone Graft Substitutes)
- Bailey and Love's Short Practice of Surgery 28th Ed, Chapter on Fracture Healing
Fracture healing line pencil diagram simple
Generating Image
This is a shared conversation. Sign in to Orris to start your own chat.